 |
BioWorld Today: Tigris Licenses Aminoflavone Prodrug For Cancer From NIH Read
- July 17, 2006 - Tigris Pharmaceuticals Broadens Oncology Pipeline With License Agreement for Phase 1 Compound From the National Institutes of Health Read
- July 12, 2006 - Tigris Pharmaceuticals Completes License Agreements for the Exclusive Rights to Novel, Targeted Cancer Compounds Read
- April 6, 2006 - Tigris Pharmaceuticals Initiates a Multi-Center Phase II Clinical Trial of A-007 in Patients with High-Grade Cervical Intraepithelial Neoplasia (CIN) Read
- October 17, 2005 - Tigris Pharmaceuticals Raises $11.6 Million in Private Placement Read
- September 22, 2005 - Binh Nguyen, M.D., Ph.D. named VP of Clinical Development and Regulatory Affairs of Tigris Pharmaceuticals Read
- September 9, 2005 - NCI Awards $2.3 Million Grant to Fund Development of A-007 Read
- September 1, 2005 - Tigris Pharmaceuticals Initiates Multi-Center Phase I/II Study of A-007 in Patients with Anal High-Grade Squamous Intraepithelial Lesions Read
- August 31, 2005 - Anne E. White named Chief Operating Officer and VP of Clinical Operations of Tigris Pharmaceuticals Read
- August 8, 2005 - Edmundo Muniz, M.D., Ph.D. named President and CEO of Tigris Pharmaceuticals Read
- March 16, 2005 - Tigris Pharmaceuticals Announces License Agreement for Exclusive Rights to A-007 Read
|
